Treace Medical Concepts Inc.
TMCI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TMCI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TMCI
Treace Medical Concepts Inc. is a medical device company focused on minimally invasive surgical solutions for bunion correction, with a history of operating losses and an accumulated deficit of $249.0 million as of December 31, 2025 [sec_mda · as of 2026-02-27].
Key risk: Accumulated deficit and losses
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 4 clinical trials for Treace Medical Concepts Inc..
Treace Medical Concepts Inc. is a medical device company focused on minimally invasive surgical solutions for bunion correction, with a history of operating losses and an accumulated deficit of $249.0 million as of December 31, 2025 [sec_mda · as of 2026-02-27].
- Cash and equivalents of $12.6M as of 2026-06-30, with total revenue of $45.4M and net loss of -$15.9M for the period [sec].
- Shareholders' equity of $87.3M and total debt of $59.2M as of 2026-06-30 [sec].
- Accumulated deficit of $249.0 million as of December 31, 2025 [sec_mda · as of 2026-02-27].
- Company expects to continue incurring significant sales, marketing, and product development expenses [sec_mda · as of 2026-02-27].
What works
- Existing cash, cash equivalents, marketable securities, and available debt borrowings are expected to fund operations for at least the next twelve months [sec_mda · as of 2025-11-06].
- The company has a focused product portfolio in the bunion correction market, a specialized surgical niche [sec_mda · as of 2025-02-27].
What to weigh
- The company has a history of operating losses and an accumulated deficit of $249.0 million as of December 31, 2025 [sec_mda · as of 2026-02-27].
- Revenue growth may be constrained as the company focuses on achieving profitability metrics, potentially slowing the pace of revenue growth [sec_mda · as of 2026-02-27].
- The company relies on single-source suppliers for materials and components, which poses a supply chain risk [sec_mda · as of 2026-05-08].
- Product liability lawsuits and regulatory compliance (FDA inspections) represent ongoing operational risks [sec_mda · as of 2025-02-27].
From the filings
Quoted directly from source documents.
The company has an accumulated deficit of $249.0 million as of December 31, 2025.
“As of December 31, 2025, we had an accumulated deficit of $249.0 million”
SEC MD&A · February 27, 2026
The company expects to continue incurring significant expenses.
“We expect to continue to incur significant sales and marketing, medical education, product development, clinical and regulatory, and other expenses.”
SEC MD&A · February 27, 2026
The company believes existing resources will fund operations for at least twelve months.
“Based upon our current operating plan, we believe that our existing cash, cash equivalents, marketable securities, and available debt borrowings will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months.”
SEC MD&A · November 6, 2025
The company faces risks from single-source suppliers.
“the ability to obtain adequate supplies of materials and components for our products, including from single-source suppliers”
SEC MD&A · May 8, 2026
Risks & what to watch (4)›
Key risks
- Accumulated deficit and losses — Accumulated deficit of $249.0M as of Dec 31, 2025; net loss of -$15.9M in latest period [sec_mda · as of 2026-02-27] [sec].
- Single-source supplier dependency — Reliance on single-source suppliers for materials and components could disrupt production [sec_mda · as of 2026-05-08].
- Product liability and regulatory risk — Product liability lawsuits and FDA compliance failures could lead to fines, recalls, or reputational damage [sec_mda · as of 2025-02-27].
- Revenue growth constraints — Focus on profitability may slow revenue growth; revenue could decline [sec_mda · as of 2026-02-27].
What to watch
- Revenue growth trajectory and ability to achieve profitability, given the focus on constraining investments [sec_mda · as of 2026-02-27].
- Cash runway and potential need for additional debt or equity financing to support operations [sec_mda · as of 2025-11-06].
- Supply chain stability, particularly regarding single-source suppliers [sec_mda · as of 2026-05-08].
- Outcome of any product liability lawsuits or FDA regulatory actions [sec_mda · as of 2025-02-27].
Sources: SEC MD&A · Generated August 23, 2026 · How we verify sources →
Run Treace Medical Concepts Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Treace Medical Concepts Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
42.4 months
D/E 1.67 · 0% dilution
Lead: Approved
1 candidate
No upcoming catalysts tracked
12 buys · 0 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
116
Total value held
$46.8M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 6,364,000 | $8.5M |
| gagnon securities llc | 5,201,886 | $7.0M |
| blackrock, inc. | 3,340,023 | $4.5M |
| bank of america corp /de/ | 3,214,293 | $4.3M |
| vanguard capital management llc | 2,923,014 | $3.9M |
| state street corp | 1,235,518 | $1.7M |
| millennium management llc | 1,148,115 | $1.5M |
| aqr capital management llc | 1,061,840 | $1.4M |
| geode capital management, llc | 1,010,843 | $1.4M |
| d. e. shaw & co., inc. | 841,269 | $1.1M |
Showing top 10 of 116 institutional holders of Treace Medical Concepts Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 12, 2026- % of float
- 7.7%
- Days to cover
- 4.3
- Shares short
- 3,961,725
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TMCI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Treace Medical Concepts Inc.?
Treace Medical Concepts Inc. is a medical device company focused on minimally invasive surgical solutions for bunion correction, with a history of operating losses and an accumulated deficit of $249.0 million as of December 31, 2025 [sec_mda · as of 2026-02-27].
What is Treace Medical Concepts Inc.'s lead drug candidate?
Treace Medical Concepts Inc.'s most advanced tracked candidate is lapiplasty (Approved) for Bunions.
Who is the CEO of Treace Medical Concepts Inc.?
Mr. John T. Treace is the chief executive officer of Treace Medical Concepts Inc. (TMCI).
Where is Treace Medical Concepts Inc. headquartered?
Treace Medical Concepts Inc. (TMCI) is headquartered in Ponte Vedra, FL, United States.
What therapeutic areas does Treace Medical Concepts Inc. focus on?
Treace Medical Concepts Inc. develops therapies across Oncology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.